General paperInhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: Effect of Ebrotidine (cas 100981-43-9)

Add time:08/22/2019    Source:sciencedirect.com

1.1. H. pylori infection causes the loss of mucus coat continuity and its patchy appearance. Here, we present evidence that the bacterium, through its cell wall lipopolysaccharide, disrupts the interaction between mucin and its mucosal receptor, and that ebrotidine is capable of counteracting this process.2.2. The receptor for mucin, isolated from the solubilized gastric epithelial cell membrane by affinity chromatography on Sepharose-bound wheat germ agglutinin, displayed a molecular weight of 97 kDa and exhibited specific affinity towards mucin-coated surface.3.3. The mucin binding to the receptor was susceptible to the inhibitin by H. pylori lipopolysaccharide and reached a maximum of 91%. This effect of the lipopolysaccharide was counteracted by ebrotidine, which caused a dose-dependent relief of the lipopolysaccharide inhibitory effect with maximum restoration in mucin-receptor binding of 51% at 60 μl/ml ebrotidine.4.4. The results show that H. pylori, through its lipopolysaccharide, is capable of disrupting the integrity of mucus perimeter of gastric mucosal defense and that antiulcer agent, ebrotidine, counteracts this untoward effect.

We also recommend Trading Suppliers and Manufacturers of Ebrotidine (cas 100981-43-9). Pls Click Website Link as below: cas 100981-43-9 suppliers

Prev:General paperEnhancement in the protective qualities of gastric mucus by Ebrotidine (cas 100981-43-9) during duodenal ulcer healing
Next:General paperEffect of Ebrotidine (cas 100981-43-9) on the synthesis and secretion of gastric sulfomucin)